Ascentage Pharma Group International (HKG:6855)
Hong Kong
· Delayed Price · Currency is HKD 63.55
+2.70 (4.44%)
At close: Dec 5, 2025
HKG:6855 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 390.6 | 980.65 | 221.98 | 209.71 | 27.91 | 12.45 | Upgrade
|
| Revenue Growth (YoY) | -56.75% | 341.77% | 5.85% | 651.38% | 124.18% | -14.21% | Upgrade
|
| Cost of Revenue | 35.68 | 29.09 | 30.54 | 22 | 3.33 | 1.97 | Upgrade
|
| Gross Profit | 354.93 | 951.57 | 191.44 | 187.71 | 24.58 | 10.48 | Upgrade
|
| Selling, General & Admin | 443.97 | 383.12 | 376.46 | 328.02 | 191.26 | 130.34 | Upgrade
|
| Research & Development | 1,032 | 947.25 | 706.97 | 743.1 | 766.49 | 564.57 | Upgrade
|
| Operating Expenses | 1,476 | 1,330 | 1,083 | 1,071 | 957.75 | 694.91 | Upgrade
|
| Operating Income | -1,121 | -378.8 | -891.99 | -883.41 | -933.17 | -684.43 | Upgrade
|
| Interest Expense | -58.18 | -64.46 | -96.06 | -52.79 | -16.73 | -6.26 | Upgrade
|
| Interest & Investment Income | 59.9 | 37.84 | 32.41 | 9.73 | 7.11 | 5.22 | Upgrade
|
| Earnings From Equity Investments | 0.97 | -0.28 | 1.08 | -0.28 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 6.69 | 6.69 | 1.62 | -2.64 | 9.91 | 17.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -31.2 | 4.63 | 20.78 | 49.91 | 139.47 | 19 | Upgrade
|
| EBT Excluding Unusual Items | -1,143 | -394.37 | -932.17 | -879.48 | -793.41 | -649.38 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.83 | -0.83 | -0.7 | -9.77 | -20.89 | -3.75 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.05 | -0.05 | 0 | 2.07 | -0.03 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -17.92 | -22.33 | Upgrade
|
| Pretax Income | -1,143 | -395.26 | -932.86 | -887.17 | -832.25 | -675.45 | Upgrade
|
| Income Tax Expense | 15.87 | 10.43 | -7.15 | -4.25 | -49.83 | 2.16 | Upgrade
|
| Earnings From Continuing Operations | -1,159 | -405.68 | -925.71 | -882.92 | -782.42 | -677.61 | Upgrade
|
| Minority Interest in Earnings | 0.13 | 0.25 | 0.08 | - | - | - | Upgrade
|
| Net Income | -1,159 | -405.43 | -925.64 | -882.92 | -782.42 | -677.61 | Upgrade
|
| Net Income to Common | -1,159 | -405.43 | -925.64 | -882.92 | -782.42 | -677.61 | Upgrade
|
| Shares Outstanding (Basic) | 327 | 302 | 282 | 264 | 255 | 216 | Upgrade
|
| Shares Outstanding (Diluted) | 327 | 302 | 282 | 264 | 255 | 216 | Upgrade
|
| Shares Change (YoY) | 12.40% | 7.00% | 7.07% | 3.56% | 17.93% | 84.97% | Upgrade
|
| EPS (Basic) | -3.55 | -1.34 | -3.28 | -3.35 | -3.07 | -3.14 | Upgrade
|
| EPS (Diluted) | -3.55 | -1.34 | -3.28 | -3.35 | -3.07 | -3.14 | Upgrade
|
| Free Cash Flow | -216.89 | -135.65 | -772.19 | -857.2 | -1,040 | -859.88 | Upgrade
|
| Free Cash Flow Per Share | -0.66 | -0.45 | -2.73 | -3.25 | -4.08 | -3.98 | Upgrade
|
| Gross Margin | 90.87% | 97.03% | 86.24% | 89.51% | 88.08% | 84.21% | Upgrade
|
| Operating Margin | -286.93% | -38.63% | -401.83% | -421.25% | -3343.50% | -5497.42% | Upgrade
|
| Profit Margin | -296.77% | -41.34% | -416.98% | -421.02% | -2803.38% | -5442.62% | Upgrade
|
| Free Cash Flow Margin | -55.53% | -13.83% | -347.86% | -408.75% | -3726.60% | -6906.64% | Upgrade
|
| EBITDA | -1,044 | -298.87 | -812.82 | -835.99 | -915.99 | -667.46 | Upgrade
|
| EBITDA Margin | -267.32% | -30.48% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 76.61 | 79.94 | 79.17 | 47.42 | 17.18 | 16.97 | Upgrade
|
| EBIT | -1,121 | -378.8 | -891.99 | -883.41 | -933.17 | -684.43 | Upgrade
|
| EBIT Margin | -286.93% | -38.63% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.